NEW YORK (GenomeWeb) – Protea Biosciences has licensed a mass spectrometry-based technology from Yale University aimed at improving diagnosis of melanoma.

The Morgantown, West Virginia-based firm is developing a test that will use proteomic mass spec imaging (MSI), pioneered by Yale Dermatology Professor Rossitza Lazova and Protea's Erin Seeley.

According to the partners, the imaging technology allows researchers to identify hundreds of specific proteins in tissue, which can help distinguish between cancerous melanomas and benign moles, also called melanocytic nevi.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.